PSY43 - Cost-Utility Analysis (CUA) of Belimumab (BEL) in the Treatment of Adult Patients with Active, Autoantibody-Positive Systemic Lupus Erythematosus (SLE)
| Autor: | Walczak, J., Kopel, J., Sołtys, E., Dziurda, D. |
|---|---|
| Zdroj: | In Value in Health November 2013 16(7):A385-A385 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect